A month after announcing a partnership with Regeneron to advance its lead gene editor, Tessera Therapeutics has disclosed it will lay off 90 employees. Endpoints News first reported the cuts. Several employees told Endpoints the layoffs will affect about 35% of the workforce. The cuts follow a 17% reduction in 2025 and 13% downsizing in 2024.
All entries for: Respiratory Diseases
January 3, 2026
GSK
Layoffs
San Francisco, CA
50,001+ employees
Up to 350 people across GSK’s U.S. and U.K. workforces could lose their jobs as the pharma reorients its investments with its priorities. The layoffs are expected to affect fewer than 70 individuals in the US, and fewer than 50 in the UK, according to Fierce.
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
November 12, 2025
CalciMedica, Inc.
Neutral Outlook
La Jolla, California
1-50 employees
For example, the Inflation Reduction Act (IRA) passed by Congress authorizes the Secretary of the Department of HHS to negotiate prices directly with participating manufacturers for selected medicines covered by Medicare even if these medicines are protected by an existing patent. For small molecule medicines, the process begins seven years after initial approval by the FDA. While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.
Disease Area: Chronic Disease, Gastrointestinal, Immune Diseases, Multiple, Respiratory Diseases
Drug Type: Biologic, Small Molecule
November 6, 2025
Cidara Therapeutics, Inc.
Neutral Outlook
San Diego, CA
1-50 employees
For example, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program
Disease Area: Infectious Diseases, Oncology, Respiratory Diseases
Drug Type: Biologic
November 4, 2025
Vertex Pharmaceuticals
Neutral Outlook
Providence, RI
5,001-10,000 employees
We cannot, however, predict how changes in the law, including through the Inflation Reduction Act of 2022 and passage of state laws (e.g., transparency laws and prescription drug affordability boards), will affect our ability to negotiate successfully with third-party payors and distribute our products.
Disease Area: Endocrinology, Hematology, Multiple, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
October 29, 2025
United Therapeutics
Neutral Outlook
Silver Spring, MD
1,001-5,000 employees
Our ability to maintain attractive pricing and reimbursement levels for our products, in light of increasing competition, including from generic products, and pressure from government and other payers to decrease the costs associated with healthcare, including the potential impact of the Inflation Reduction Act of 2022 (IRA) on our business and President Trump’s most favored nation pricing initiative.
Disease Area: Cardiology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
October 2, 2025
GSK
Layoffs
San Francisco, CA
50,001+ employees
Pharma giant GSK continues to shed employees, this time with an 8-person round of layoffs at its San Francisco, California site, according to a Worker Adjustment and Retraining Notification posting. The terminations were effective Sept. 29. GSK has enacted a couple of other workforce reductions this year.
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
August 21, 2025
CSL
Layoffs
King of Prussia, PA
10,001-50,000 employees
Australian multinational CSL is parting ways with 15% of its workforce as part of a sweeping restructuring push, with an eye toward streamlining its operations and boosting its clinical and commercial performance.
As part of this strategic initiative, CSL will also spin off its vaccines business, CSL Seqirus, into its own independent entity, effective before its 2026 financial year ends in June next year. The pharma will also cut back on its overall expenditure, “including consolidation of R&D footprint.”
Disease Area: Hematology, Immune Diseases, Neurological Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
August 14, 2025
Tvardi Therapeutics Inc
Neutral Outlook
Sugar Land, TX
1-50 employees
President Biden signed the Inflation Reduction Act of 2022 (IRA), into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or congressional challenges in the future.
Disease Area: Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Small Molecule
August 12, 2025
Theravance Biopharma, Inc.
Neutral Outlook
South San Francisco, California
201-500 employees
The coverage gap was eliminated effective 2025 under the Inflation Reduction Act of 2022 (the “IRA”) and was replaced with a new manufacturer discount program), rules regarding prescription drug benefits under the health insurance exchanges, changes to the Medicare Drug Rebate program, expansion of the Public Health Service Act’s 340B drug pricing program, fraud and abuse and enforcement
Disease Area: Respiratory Diseases
Drug Type: Biologic, Small Molecule